- 関
- hematologic malignancy、hematological malignancy、hematological neoplasm、hematopoietic malignancy、hematopoietic neoplasm
WordNet
- of or relating to or involved in hematology (同)haematological, hematological
PrepTutorEJDIC
- (体内にできる)新生物;腫瘍(しゅよう)
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 造血腫瘍の分類 classification of the hematopoietic neoplasms
- 2. 骨髄増殖性腫瘍の概要 overview of the myeloproliferative neoplasms
- 3. 多発性骨髄腫の臨床的特徴、検査所見、および診断 clinical features laboratory manifestations and diagnosis of multiple myeloma
- 4. 小児および思春期における急性リンパ芽球性白血病の転帰に関する概要 overview of the outcome of acute lymphoblastic leukemia in children and adolescents
- 5. 慢性骨髄性白血病の臨床症状および診断 clinical manifestations and diagnosis of chronic myeloid leukemia
English Journal
- Radiation-exposed populations: who, why, and how to study.
- Simon SL, Linet MS.Author information *Division of Cancer Epidemiology and Genetics, National CancerInstitute, National Institutes of Health, 6120 Executive Blvd, Bethesda, MD.AbstractEveryone is exposed to natural and manmade ionizing radiation that can originate from sources in the environment and in medical and occupational settings. There is notable variation, however, among individuals and across populations in the types of sources of radiation and in the frequency, level, and duration of exposure. Adverse health effects associated with radiation exposure have been known for decades, and ionizing radiation exposure has been linked with a broad range of different types of cancer and benign neoplasms as well as birth defects, reproductive effects, and diseases of the circulatory, hematologic, and neurologic systems. Our present understanding of radiation-related health risks derives primarily from multidisciplinary health risk (epidemiologic) studies that provide the key information on radiation-associated health outcomes, quantify radiation-related disease risks, and enhance understanding of mechanisms of radiation-related disease pathogenesis. Such information is central to quantifying risks in relation to benefits; addressing public concerns, including societal and clinical needs in relation to radiation exposure; and providing the database needed for establishing recommendations for radiation protection. Because of the importance of determining risks compared to benefits for all situations where exposure to ionizing radiation might result, it is useful for planning new health risks studies to categorize exposed populations according to the sources and types of radiation. This paper describes a wide range of populations exposed to radiation and the motivation and key methodological criteria that drive the rationale and priority of studying such populations. Also, discussed are alternative methods for evaluating radiation-related health risks in these populations, with a major focus on epidemiologic approaches. This paper concludes with a short summary of major highlights from radiation epidemiologic research and important unanswered questions.Introduction of Exposed Populations (Video 1:29, http://links.lww.com/HP/A22).
- Health physics.Health Phys.2014 Feb;106(2):182-95. doi: 10.1097/HP.0000000000000006.
- Everyone is exposed to natural and manmade ionizing radiation that can originate from sources in the environment and in medical and occupational settings. There is notable variation, however, among individuals and across populations in the types of sources of radiation and in the frequency, level, a
- PMID 24378492
- Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc.
- Stoddart A, Wang J, Fernald AA, Karrison T, Anastasi J, Le Beau MM.Author information Department of Medicine.AbstractTherapy-related myeloid neoplasms (t-MN) are a late complication of the successful use of cytotoxic therapy for patients with cancer. A heterozygous deletions of the long arm of chromosome 5 [del(5q)], observed in 40% of patients, is associated with prior exposure to alkylating agents, and a high frequency of TP53 loss or mutation. In previous studies, we demonstrated that haploinsufficiency of 2 del(5q) genes, Egr1, and Apc, individually play a role in the pathogenesis of hematologic disease in mice. We now show that loss of one copy of Egr1 or Tp53 in an Apc haploinsufficient background (Apc (del/+)) accelerated the development of a macrocytic anemia with monocytosis, early features of t-MN. The development of anemia was significantly accelerated by treatment of mice with the alkylating agent, N-ethyl-N-nitrosourea (ENU), regardless of the levels of expression of Egr1 and Tp53. Transplantation of either wild type; Egr1(+/-); Tp53(+/-); Apc(del/+); or Egr1(+/-), Apc(del/+) bone marrow cells into lethally irradiated Apc(del/+) recipients resulted in rapid development of anemia that was further accelerated by administration of ENU to recipients, demonstrating that the Apc(del/+)-induced anemia was cell extrinsic and potentiated by ENU mutagenesis. These data emphasize the synergistic role of cell intrinsic and cell extrinsic (microenvironment) factors in the pathogenesis of t-MN, and raise awareness of the deleterious effects of cytotoxic therapy on the stromal microenvironment.
- Blood.Blood.2014 Jan 9;123(2):228-38. doi: 10.1182/blood-2013-05-506568. Epub 2013 Nov 21.
- Therapy-related myeloid neoplasms (t-MN) are a late complication of the successful use of cytotoxic therapy for patients with cancer. A heterozygous deletions of the long arm of chromosome 5 [del(5q)], observed in 40% of patients, is associated with prior exposure to alkylating agents, and a high fr
- PMID 24264229
- Factors Associated With Futile End-Of-Life Intensive Care in a Cancer Hospital.
- Cruz VM, Camalionte L, Caruso P.Author information 1ICU, AC Camargo Cancer Center, São Paulo, Brazil.AbstractBackground:Management of critically ill patients involves weighing potential benefit of advanced life support against preserving quality of life, avoidance of futile measures and rational use of resources.Aim:Our study aims to identify the predisposing factors involved in the institution and maintenance of futile intensive care support in terminally ill cancer patients in whom no additional treatment for the malignant disease would be offered.Design:We retrospectively analysed the medical records of patients who died in a tertiary cancer hospital (Hospital A C Camargo, São Paulo, Brazil) during an eight month period. Medical futility was defined when a patient, despite having been stated in the hospital records as having no possible lifespan extending treatment, was admitted to intensive care and received advanced life support. These cases were compared to controls who received palliative end-of-life care.
- The American journal of hospice & palliative care.Am J Hosp Palliat Care.2014 Jan 7. [Epub ahead of print]
- Background:Management of critically ill patients involves weighing potential benefit of advanced life support against preserving quality of life, avoidance of futile measures and rational use of resources.Aim:Our study aims to identify the predisposing factors involved in the institution and mainten
- PMID 24399608
Japanese Journal
- T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis
- Yoshioka Yuriko,Nagao Miho,Saitoh Toshiharu,Yoshioka Satoshi,Tsunemine Hiroko,Itoh Kiminari,Kodaka Taiichi,Takahashi Takayuki
- Journal of Clinical and Experimental Hematopathology 55(1), 17-21, 2015
- … T-cell prolymphocytic leukemia, small cell variant (T-PLL-s), is a rare lymphoid neoplasm associated with a poor prognosis. … Hematologic examination revealed a white blood cell count of 17.9 × 109/L with 81.2% mature lymphocytes, which were small with a high nuclear/cytoplasmic ratio, lacking a nucleolus and cytoplasmic granules. …
- NAID 130005083792
- Spontaneous Regression of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Followed by Acute Monocytic Leukemia Evolving from Myelodysplastic Syndrome
- Yasuda Hajime,Takaku Tomoiku,Tomomatsu Junichi,Hosone Masaru,Tanaka Hiroyuki,Komatsu Norio
- Internal Medicine 53(23), 2717-2720, 2014
- … Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy arising from plasmacytoid dendritic cell precursors. …
- NAID 130004713269
- Leukemic Manifestation of Blastic Plasmacytoid Dendritic Cell Neoplasm Lacking Skin Lesion : A Borderline Case between Acute Monocytic Leukemia
- TAKIUCHI Yoko,MARUOKA Hayato,AOKI Kazunari,KATO Aiko,ONO Yuichiro,NAGANO Seiji,ARIMA Hiroshi,INOUE Daichi,MORI Minako,TABATA Sumie,YANAGITA Soshi,MATSUSHITA Akiko,NISHIO Mari,IMAI Yukihiro,ITO Kiminari,FUJITA Haruyuki,KADOWAKI Norimitsu,ISHIKAWA Takayuki,TAKAHASHI Takayuki,Takahashi Takayuki
- Journal of clinical and experimental hematopathology 52(2), 107-111, 2012-10-01
- … Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with a poor prognosis. …
- NAID 10031120434
Related Links
- ... Hematologic Neoplasm; Hematological Malignancies; Hematological Malignancy; Hematological Neoplasm; Hematological Neoplasms; Hematopoietic Malignancies; Hematopoietic Malignancy; Hematopoietic Neoplasm; ; ; ; ; ...
- Hematologic Neoplasms information including symptoms, causes, diseases, symptoms, treatments, and other medical and health issues. ... Introduction: Hematologic Neoplasms Description of Hematologic Neoplasms Hematologic ...
Related Pictures
★リンクテーブル★
| リンク元 | 「hematologic malignancy」「hematological malignancy」「hematopoietic malignancy」「hematopoietic neoplasm」「hematological neoplasm」 |
| 関連記事 | 「neoplasm」「hematologic」 |
「hematologic malignancy」
- 関
- haematopoietic neoplasm、hematologic neoplasm、hematological malignancy、hematological neoplasm、hematopoietic malignancy、hematopoietic neoplasm
「hematological malignancy」
- 関
- haematopoietic neoplasm、hematologic malignancy、hematologic neoplasm、hematological neoplasm、hematopoietic malignancy、hematopoietic neoplasm
「hematopoietic malignancy」
- 関
- haematopoietic neoplasm、hematologic malignancy、hematologic neoplasm、hematological malignancy、hematological neoplasm、hematopoietic neoplasm
「hematopoietic neoplasm」
- 関
- haematopoietic neoplasm、hematologic malignancy、hematologic neoplasm、hematological malignancy、hematological neoplasm、hematopoietic malignancy
「hematological neoplasm」
- 関
- hematologic malignancy、hematologic neoplasm、hematological malignancy、hematopoietic malignancy、hematopoietic neoplasm
「neoplasm」
- n.
「hematologic」
- 血液学的な